FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileRevolution Medicines, Inc. Warrant
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
RVMDW
Revolution Medicines, Inc. Warrant Stock AnalysisComprehensive stock analysis for Revolution Medicines, Inc. Warrant (RVMDW) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisRVMDW
RVMDW
Revolution Medicines, Inc. Warrant
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
RVMDW
  1. Home
  2. Stocks
  3. Revolution Medicines, Inc. Warrant

Revolution Medicines, Inc. Warrant

🇺🇸RVMDW•NASDAQ

Revolution Medicines, Inc. Warrant

🇺🇸RVMDW•NASDAQ
Market cap
$35.42B

Your view on RVMDW

Mkt Cap
$35.42B
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Revolution Medicines, Inc. Warrant

Industry
Biotechnology
Sector
Healthcare
CEO
Mark A. Goldsmith
Headquarters
700 Saginaw Drive, Redwood City, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Mark A. Goldsmith
Headquarters
700 Saginaw Drive, Redwood City, CA, US
Description

Revolution Medicines, Inc. is a biopharmaceutical company in the clinical development phase, concentrating on creating innovative, precisely targeted therapies for cancers driven by RAS pathway dysregulation.

The firm's drug development portfolio features both RAS(ON) inhibitors, which are designed for potential use as single agents, in conjunction with other RAS(ON) inhibitors, or alongside RAS companion inhibitors and various therapeutic compounds.

Additionally, its pipeline includes dedicated RAS companion inhibitors intended for synergistic treatment approaches. Among its RAS(ON) inhibitors currently in Phase 1 clinical trials are RMC-6236 (targeting a broad spectrum of RAS mutations), RMC-6291 (specific to G12C), and RMC-9805 (for G12D).

Further compounds in preclinical or early development include RMC-5127 (for G12V), RMC-0708 (for Q61H), and RMC-8839 (for G13C), along with ongoing programs focused on G12R and other distinct molecular targets.

In the realm of RAS companion inhibitors, RMC-4630 is advancing through Phase 2 clinical assessment, while RMC-5552 is undergoing Phase 1 evaluation. Revolution Medicines, Inc. was founded in 2014 and operates from its headquarters in Redwood City, California.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Revolution Medicines, Inc. Warrant. Starting points for Revolution Medicines, Inc. Warrant: EPS -$8.70, beta 1.40 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Revolution Medicines, Inc. Warrant. Trailing twelve-month EPS for Revolution Medicines, Inc. Warrant stands at -$8.70. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Revolution Medicines, Inc. Warrant. Revolution Medicines, Inc. Warrant has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold RVMDW12 companies
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
ARUXFAcrux LimitedHealthcareOTC$1.8M
ARVNArvinas, Inc.HealthcareNASDAQ$423.0M
ARWRArrowhead Pharmaceuticals, Inc.HealthcareNASDAQ$5.8B
ASBPAspire Biopharma Holdings, Inc.HealthcareNASDAQ$822,602
ASBPWAspire Biopharma Holdings, Inc.HealthcareNASDAQ$121,920
ASCLFAscletis Pharma Inc.HealthcareOTC$2.1B
ASEP.CNAsep Medical Holdings IncHealthcareCNQ—
ASMBAssembly Biosciences, Inc.HealthcareNASDAQ$454.4M
ASNDAscendis Pharma A/SHealthcareNASDAQ$16.6B
ASPEAspen Neuroscience Inc.HealthcareNASDAQ$361.2M
ASPHFAscentage Pharma Group InternationalHealthcareOTC$3.2B
ATAIAtai Life Sciences N.V.HealthcareNASDAQ$2.7B
Ownership & News

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Revolution Medicines, Inc. Warrant executives and directors. Shares of Revolution Medicines, Inc. Warrant have traded between $0.39 and $11.50 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Revolution Medicines, Inc. Warrant. Coverage tracks Revolution Medicines, Inc. Warrant within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Revolution Medicines, Inc. Warrant.

RVMDW AnalysisFair
Past
5
Growth
1
Health
4
Profit
1
Value
1